Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stake Lifted by CenterBook Partners LP

CenterBook Partners LP raised its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 98.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 305,599 shares of the biopharmaceutical company’s stock after buying an additional 151,511 shares during the quarter. CenterBook Partners LP owned approximately 0.54% of Agios Pharmaceuticals worth $10,042,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $53,000. KBC Group NV increased its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the period. AlphaQuest LLC raised its stake in Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 2,338 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $202,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on AGIO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 price target for the company. Finally, Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $24.53 on Wednesday. The company has a 50-day moving average of $32.03 and a two-hundred day moving average of $39.78. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 2.16 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a one year low of $24.03 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.